Komori
Share Issuance and Disposal4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions

In July 2026, 760 of the 13th Stock Acquisition Rights were exercised, and 76,000 new shares were delivered. As of the end of the month, 8,338 Stock Acquisition Rights remained unexercised.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
76000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

New shares 76,000 shares / Treasury shares 0 shares

Terms of the stock acquisition rights
Exercise price
¥80 (exercise price for July 2026; details of the adjustment clause are not disclosed in this document)
Number of Stock Acquisition Rights
Total number issued 100,000 (calculated based on 760 representing 0.76% of the total issued) / Unexercised balance 9,098 at the end of the month preceding the subject month; 8,338 at the end of the subject month
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financing
Timing 31 July 2025 / Type Issuance of the 13th Series Stock Acquisition Rights with an Exercise Price Adjustment Clause / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNew shares 76,000 shares / Treasury shares 0 shares
Total number of issued shares57,483,412 shares (including 11,387 treasury shares) → Not disclosed
Exercise price¥80 (exercise price for July 2026; details of the adjustment clause are not disclosed in this document)
Number of Stock Acquisition RightsTotal number issued 100,000 (calculated based on 760 representing 0.76% of the total issued) / Unexercised balance 9,098 at the end of the month preceding the subject month; 8,338 at the end of the subject month
Procedures under the Corporate Code of ConductThe disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financingTiming 31 July 2025 / Type Issuance of the 13th Series Stock Acquisition Rights with an Exercise Price Adjustment Clause / Amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status for July 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori